A phase i open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers

Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2014, Pages 555-562

  Ruiz Garcia, Ana ^a   Giri, Nagdeep ^a   Labadie, Robert R ^a   Ni, Grace ^a   Boutros, Tanya ^a   Richie, Nicole ^a   Kocinsky, Hetal S ^a   Checchio, Tina M ^a   Bello, Carlo L ^a  

^a PFIZER INC   (United States)

Author keywords

CYP2D6; Dacomitinib; drug interaction; healthy volunteers; paroxetine

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DACOMITINIB; PAROXETINE; CYTOCHROME P450 2D6 INHIBITOR; QUINAZOLINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLURRED VISION; BODY MASS; BURNING SENSATION; CHILL; CONSTIPATION; CONTUSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EYE PAIN; FATIGUE; FEMALE; GLUTATHIONE METABOLISM; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MUSCLE WEAKNESS; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PTOSIS; RASH; RHINORRHEA; RISK ASSESSMENT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UNSPECIFIED SIDE EFFECT; VERTIGO; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PAROXETINE; QUINAZOLINONES; YOUNG ADULT;

EID: 84898655989     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.243     Document Type: Article

References (17)

1. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007; 67: 11924-11932.
2. Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011; 17: 1131-1139.
3. Jänne PA, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial. J Clin Oncol. 2009; 27 (Suppl 15):Abstr. 8063.
4. Park K, Heo DS, Cho BC, et al. Updated safety and efficacy results of a phase 1/2 study of PF-00299804 in Korean patients with NSCLC who experienced disease progression on platinum-based chemotherapy plus gefitinib or erlotinib. Presented at the 4th Asia Pacific Lung Cancer Conference (APLCC), Seoul, Korea, December 2-4, 2010 (Abstr. O-018).
5. Takahashi T, Boku N, Murakami H., Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012; 30: 2352-2363.
6. Bello CL, Smith E, Ruiz-Garcia A, Ni G, Alvey C, Loi CM., A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemother Pharmacol 2013; 72: 379-385.
7. Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3337-3344.
8. Abdul Razak AR, Soulières D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2013; 24: 761-769.
9. Bello CL, LaBadie RR, Ni G, Boutros T, McCormick C, Ndongo MN., The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol 2012; 69: 991-997.
10. Bibi Z., Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 2008; 5: 1-8.
11. Teh LK, Bertilsson L., Pharmacogenomics of CYP2 D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012; 27: 55-67.
12. Venkatakrishnan K, Obach RS., In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005; 33: 845-852. (Pubitemid 40686639)
13. Center for Drug Evaluation and Research. Guidance for industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Administration. February 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf Accessed January 4, 2013.
14. Livezey M, Nagy LD, Diffenderfer LE, et al. Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators. Drug Metab Lett 2012; 6: 7-14.
15. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ., Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 289-293. (Pubitemid 36249683)
16. GlaxoSmithKline. PAXIL® (paroxetine hydrochloride) Tablets and Oral Suspension. Prescribing Information. January 2013. Available at: http://us.gsk.com/products/assets/us-paxil.pdf Accessed May 14, 2013.
17. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989; 350: 60-75. (Pubitemid 19236643)